Article (Scientific journals)
ASTEROID: regression de l'atherosclerose coronaire avec la rosuvastatine 'a une dose maximale de 40 mg par jour.
Scheen, André
2006In Revue Médicale de Liège, 61 (4), p. 267-72
Peer reviewed
 

Files


Full Text
200604_14.pdf
Publisher postprint (718.95 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Cholesterol, HDL/blood; Cholesterol, LDL/blood; Clinical Trials as Topic; Coronary Artery Disease/drug therapy/ultrasonography; Female; Fluorobenzenes/therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Male; Middle Aged; Pyrimidines/therapeutic use; Sulfonamides/therapeutic use; Ultrasonography, Interventional
Abstract :
[en] ASTEROID is a prospective, open-label blinded end-points trial aiming to assess whether very intensive statin therapy with rosuvastatin 40 mg/day could regress coronary atherosclerosis as determined by intravascular ultrasound (IVUS). This multinational study included 507 patients, among whom 349 had evaluable serial IVUS examinations at 24 months. Rosuvastatin decreased LDL cholesterol level from 130 mg/dl to 61 mg/dl (- 53.2%) and increased HDL cholesterol from 43 to 49 mg/dl (+ 14.7%). The three prespecified IVUS efficacy parameters were positively altered by rosuvastatin, demonstrating regression of coronary atherosclerosis : the mean change in percent atheroma volume (- 0.98%), the change in atheroma volume in the most diseased 10-mm subsegment me (- 6.1 mm3) and the change in total atheroma volume (- 6.8%) were all significant (p < 0,001). Adverse events were infrequent and similar to other statin trials. The present study demonstrates that a 2-year treatment with a high dose of rosuvastatin 40 mg/day is able to induce significant regression of coronary atherosclerosis as determined by IVU imaging. Further ongoing studies in the GALAXY clinical investigation programme should now demonstrate that rosuvastatin, the most potent statin to reduce LDL and increase HDL cholesterol, is also able to diminish the incidence of clinical outcomes, cardiovascular events in general and major coronary events in particular.
Disciplines :
Cardiovascular & respiratory systems
Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
ASTEROID: regression de l'atherosclerose coronaire avec la rosuvastatine 'a une dose maximale de 40 mg par jour.
Alternative titles :
[en] Clinical study of the month: ASTEROID: regression of coronary atherosclerosis with rosuvastatin at a maximal daily dose of 40 mg
Publication date :
2006
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
61
Issue :
4
Pages :
267-72
Peer reviewed :
Peer reviewed
Additional URL :
Available on ORBi :
since 23 March 2009

Statistics


Number of views
217 (0 by ULiège)
Number of downloads
418 (1 by ULiège)

Scopus citations®
 
7
Scopus citations®
without self-citations
3

Bibliography


Similar publications



Contact ORBi